




Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.4. Antihepatitis medicines > 6.4.4.2. Medicines for hepatitis C > 6.4.4.2.2. Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Codes ATC: J05AP05

Indication	Chronic hepatitis C <span style="border: 1px solid gray; padding: 2px;">Code ICD11: 1E91.1</span>
INN	Simeprevir
Type de médicament	Chemical agent
Type de liste	Liste de base
Formulations	Oral > Solid: 150 mg
Historique des statuts LME	Ajouté pour la première fois en 2015 (TRS 994) Retiré en 2019 (TRS 1021)
Sexe	Tous
Âge	Adolescents et adultes
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Lire la suite <a href="#">sur les brevets.</a> 
Wikipédia	<a href="#">Simeprevir</a> 
DrugBank	<a href="#">Simeprevir</a> 

### Résumé des preuves et recommandation du comité d'experts

The Expert Committee considered whether it was appropriate to delete non-pangenotypic treatments for hepatitis C, and recommended the deletion of simeprevir, whose place in therapy was now superseded by the pan-genotypic options. The Committee recommended that other non-pangenotypic treatments could be considered for deletion from the EML in the future.

